Goldman Sachs Cuts Price Target on United Therapeutics (UTHR), But Still Sees 30% Upside

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/21/2026

1. TGT
2. EL
3. SPY
4. WMT
5. ADI
6. ROST
7. BILL
8. MRK
9. MRNA
10. NTES

August 25, 2011 8:43 AM EDT
Get Alerts UTHR Hot Sheet
Price: $521.00 -1.54%

Rating Summary:
    17 Buy, 11 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Goldman Sachs slashed its price target on United Therapeutics Corp. (NASDAQ: UTHR) from $82 to $52 after the second Phase 3 trial of an oral formulation of its
franchise drug, Remodulin, failed to meet the primary endpoint. However, the firm is maintaining a Buy rating.

Goldman said the company's base business and net cash is worth $52, which represents approximately 30% upside from current levels.

The firm cut 2013/2014/2015 EPS estimates to $4.16/$4.19/$4.25 from $4.90/$5.37/$5.87.

For more ratings news on United Therapeutics Corp. click here and for the rating history of United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $39.91 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Goldman Sachs